TuisBSLN • SWX
add
Basilea Pharmaceutica AG Allschwil
Vorige sluiting
CHF 41,15
Dagwisseling
CHF 40,60 - CHF 41,45
Jaarwisseling
CHF 32,00 - CHF 49,00
Markkapitalisasie
540,62 m CHF
Gemiddelde volume
17,18 k
P/V-verhouding
47,10
Dividend-opbrengs
-
Primêre beurs
SWX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(CHF) | Des. 2023info | J/J-verandering |
---|---|---|
Inkomste | 36,36 m | -19,30% |
Bedryfskoste | 7,96 m | 12,34% |
Netto inkomste | -10,69 m | -187,82% |
Netto winsgrens | -29,41 | -208,81% |
Wins per aandeel | — | — |
EBITDA | -7,88 m | -152,08% |
Effektiewe belastingkoers | 0,08% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(CHF) | Des. 2023info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 59,93 m | -29,21% |
Totale bates | 173,29 m | -21,53% |
Totale aanspreeklikheid | 183,29 m | -24,12% |
Totale ekwiteit | -10,00 m | — |
Uitstaande aandele | 12,00 m | — |
Prys om te bespreek | -49,58 | — |
Opbrengs op bates | -11,81% | — |
Opbrengs op kapitaal | -17,26% | — |
Kontantvloei
Netto kontantverandering
(CHF) | Des. 2023info | J/J-verandering |
---|---|---|
Netto inkomste | -10,69 m | -187,82% |
Kontant van bedrywe | -3,81 m | -210,31% |
Kontant van beleggings | -322,50 k | -100,69% |
Kontant van finansiering | -20,11 m | -4,52% |
Netto kontantverandering | -24,31 m | -178,80% |
Beskikbare kontantvloei | -4,62 m | -154,24% |
Meer oor
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
The company is based in Basel, Switzerland. It has subsidiaries in France, Germany, Denmark, the People's Republic of China, Spain, the United Kingdom, and the United States of America. According to stock filings, it had 196 employees as of June 2007.
Among the company's notable products is Isavuconazole, an intravenous and oral antifungal, which received orphan drug status designation by the United States Food and Drug Administration in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus. Wikipedia
HUB
Gestig
Okt. 2000
Webwerf
Werknemers
147